Wang Xiaodong, a director at BeOne Medicines Ltd., has reported several transactions involving American Depositary Shares (ADS) of the company. This activity, disclosed in a recent SEC filing, highlights Xiaodong's active role in managing his holdings within the pharmaceutical sector.
The filing, dated October 15, 2026, reveals that Xiaodong engaged in multiple transactions on October 13, 2026, involving the sale and acquisition of shares. Notably, he sold a total of 31,027 ADS at an average price of $36.90, along with additional sales of ADS at varying prices. Following these transactions, Xiaodong retains a substantial number of shares in BeOne Medicines, indicating his continued investment in the company.
Background
BeOne Medicines Ltd. is a company focused on pharmaceutical preparations, specifically in the life sciences sector. It is listed under the Central Index Key (CIK) 0001651308. The company operates primarily from Basel, Switzerland, and has undergone significant changes in its corporate structure, previously known as BeiGene, Ltd., before a name change in August 2015.
What the Filing Says
The SEC filing details several transactions by Wang Xiaodong, including:
- Sale of 31,027 ADS at $36.90 each.
- Multiple sales of ADS at prices ranging from $348.98 to $353.325.
- Acquisition of 403,351 share options at an exercise price of $2.84.
Xiaodong's post-transaction holdings include 4,588,113 ordinary shares directly owned and additional shares held indirectly through family trusts.
Impact
This update may influence various stakeholders, including investors and analysts monitoring BeOne Medicines' performance and strategic direction. Xiaodong's ongoing involvement as a director and chair of the scientific advisory board underscores his commitment to the company's future.
What's Next
The filing does not say what happens next.